Masitinib for the treatment of mild to moderate Alzheimer's disease

dc.creatorFolch J.
dc.creatorPetrov D.
dc.creatorEttcheto M.
dc.creatorPedrós I.
dc.creatorAbad S.
dc.creatorBeas-Zarate C.
dc.creatorLazarowski A.
dc.creatorMarin M.
dc.creatorOlloquequi J.
dc.creatorAuladell C.
dc.creatorCamins A.
dc.date.accessioned2020-09-02T22:17:54Z
dc.date.accessioned2022-11-08T20:26:00Z
dc.date.available2020-09-02T22:17:54Z
dc.date.available2022-11-08T20:26:00Z
dc.date.created2020-09-02T22:17:54Z
dc.date.issued2015
dc.identifier15, 6, 587-596
dc.identifier14737175
dc.identifierhttps://hdl.handle.net/20.500.12728/4495
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5145901
dc.languageen
dc.publisherExpert Reviews Ltd.
dc.subjectAlzheimer
dc.subjectinflammation
dc.subjectmasitinib
dc.subjectneurodegeneration
dc.subjecttau
dc.subjectmasitinib
dc.subjectstem cell factor receptor
dc.subjectmasitinib
dc.subjectprotein kinase inhibitor
dc.subjectstem cell factor receptor
dc.subjectthiazole derivative
dc.subjectAlzheimer disease
dc.subjectcell interaction
dc.subjectdrug efficacy
dc.subjectdrug mechanism
dc.subjectdrug metabolism
dc.subjectglia cell
dc.subjecthuman
dc.subjectmast cell
dc.subjectnervous system inflammation
dc.subjectnonhuman
dc.subjectpharmacodynamics
dc.subjectphase 1 clinical trial (topic)
dc.subjectphase 2 clinical trial (topic)
dc.subjectphase 3 clinical trial (topic)
dc.subjectReview
dc.subjectAlzheimer disease
dc.subjectanimal
dc.subjectchemistry
dc.subjectmetabolism
dc.subjectAlzheimer Disease
dc.subjectAnimals
dc.subjectHumans
dc.subjectProtein Kinase Inhibitors
dc.subjectProto-Oncogene Proteins c-kit
dc.subjectThiazoles
dc.titleMasitinib for the treatment of mild to moderate Alzheimer's disease
dc.typeReview


Este ítem pertenece a la siguiente institución